scholarly journals Increasing Precision of Real-World Data Estimates: The Importance of A Step-Wise Process to Limit Data Collection Errors And Data Incompleteness

2015 ◽  
Vol 18 (7) ◽  
pp. A722
Author(s):  
P Kritikou ◽  
E de Cock ◽  
D Stein
Author(s):  
Martyna Bogacz ◽  
Stephane Hess ◽  
Chiara Calastri ◽  
Charisma F. Choudhury ◽  
Alexander Erath ◽  
...  

The use of virtual reality (VR) in transport research offers the opportunity to collect behavioral data in a controlled dynamic setting. VR settings are useful in the context of hypothetical situations in which real-world data does not exist or in situations which involve risk and safety issues making real-world data collection infeasible. Nevertheless, VR studies can contribute to transport-related research only if the behavior elicited in a virtual environment closely resembles real-world behavior. Importantly, as VR is a relatively new research tool, the best-practice with regards to the experimental design is still to be established. In this paper, we contribute to a better understanding of the implications of the choice of the experimental setup by comparing cycling behavior in VR between two groups of participants in similar immersive scenarios, the first group controlling the maneuvers using a keyboard and the other group riding an instrumented bicycle. We critically compare the speed, acceleration, braking and head movements of the participants in the two experiments. We also collect electroencephalography (EEG) data to compare the alpha wave amplitudes and assess the engagement levels of participants in the two settings. The results demonstrate the ability of VR to elicit behavioral patterns in line with those observed in the real-world and indicate the importance of the experimental design in a VR environment beyond the choice of audio-visual stimuli. The findings will be useful for researchers in designing the experimental setup of VR for behavioral data collection.


2009 ◽  
Vol 103 (1) ◽  
pp. 62-68
Author(s):  
Kathleen Cage Mittag ◽  
Sharon Taylor

Using activities to create and collect data is not a new idea. Teachers have been incorporating real-world data into their classes since at least the advent of the graphing calculator. Plenty of data collection activities and data sets exist, and the graphing calculator has made modeling data much easier. However, the authors were in search of a better physical model for a quadratic. We wanted students to see an actual parabola take shape in real time and then explore its characteristics, but we could not find such a hands-on model.


2020 ◽  
Vol 22 ◽  
pp. S80
Author(s):  
M. Soni ◽  
L. Marshall ◽  
R. Zaha ◽  
J. Lee ◽  
Y. Huang

2014 ◽  
Vol 17 (3) ◽  
pp. A203
Author(s):  
Y.I. Pan ◽  
G. Dieck ◽  
A. Stemhagen

2005 ◽  
Author(s):  
Igor Prislin ◽  
David Rainford ◽  
Stephen Perryman ◽  
Roy Shilling

This paper describes how the desire for real world data must be matched by an equal determination to use it efficiently and in a timely manner to benefit a facility’s operating performance, management of longer term risks, and enhance future projects. The paper addresses how balance between data collection and its use can be achieved through influencing design and operating performance.


2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Andras Inotai ◽  
Marcell Csanadi ◽  
Guenka Petrova ◽  
Maria Dimitrova ◽  
Tomasz Bochenek ◽  
...  

This policy research aims to map patient access barriers to biologic treatments, to explore how increased uptake of biosimilars may lower these hurdles and to identify factors limiting the increased utilisation of biosimilars. A policy survey was developed to review these questions in 10 Central and Eastern European (CEE) and Commonwealth of Independent States (CIS) countries. Two experts (one public and one private sector representative) from each country completed the survey. Questions were related to patient access, purchasing, clinical practice, and real-world data collection on both original biologics and biosimilars. Restrictions on the number of patients that can be treated and related waiting lists were reported as key patient access barriers. According to respondents, for both clinicians and payers the primary benefit of switching patients to biosimilars would be to treat more patients. However, concerns with therapeutic equivalence and fear of immunogenicity may reduce utilisation of biosimilars. Similar limitations in patient access to both original biologics and biosimilars raise concerns about the appropriateness and success of current biosimilar policies in CEE and CIS countries. The conceptual framework for additional real-world data collection exists in all countries which may provide a basis for future risk-management activities including vigorous pharmacovigilance data collection.


2019 ◽  
Vol 22 ◽  
pp. S833-S834
Author(s):  
R. Torres Torrejon ◽  
F. Janeke ◽  
R. Saunders

Sign in / Sign up

Export Citation Format

Share Document